Insider Selling: Eton Pharmaceuticals (NASDAQ:ETON) Insider Sells $1,626,750.00 in Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 25,000 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the sale, the insider directly owned 37,025 shares of the company’s stock, valued at approximately $2,409,216.75. This represents a 40.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

David Krempa also recently made the following trade(s):

• On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.49, for a total transaction of $1,181,630.76.
• On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.47, for a total transaction of $619,298.13.

Eton Pharmaceuticals Trading Down 0.7%

Eton Pharmaceuticals stock opened at $62.62 on Thursday. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of 164.79 and a beta of 0.86. Eton Pharmaceuticals, Inc. has a 1 year low of $14.27 and a 1 year high of $66.37. The firm’s 50 day moving average price is $44.02 and its two-hundred day moving average price is $31.37. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.24. The company had revenue of $37.59 million during the quarter, compared to the consensus estimate of $27.11 million. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. On average, research analysts predict that Eton Pharmaceuticals, Inc. will post 1.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC grew its holdings in shares of Eton Pharmaceuticals by 156.3% during the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after acquiring an additional 217,042 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Eton Pharmaceuticals by 34.9% during the first quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock valued at $2,274,000 after purchasing an additional 45,341 shares during the last quarter. Jane Street Group LLC grew its stake in Eton Pharmaceuticals by 49.1% in the first quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock valued at $1,245,000 after purchasing an additional 31,596 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Eton Pharmaceuticals by 114.5% in the second quarter. JPMorgan Chase & Co. now owns 242,580 shares of the company’s stock valued at $3,457,000 after purchasing an additional 129,467 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in Eton Pharmaceuticals in the second quarter valued at about $41,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ETON shares. Canaccord Genuity Group upped their target price on Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a report on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Friday, July 17th. Craig Hallum boosted their price objective on Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, July 28th. HC Wainwright upped their price objective on shares of Eton Pharmaceuticals from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, August 14th. Finally, B. Riley Financial reiterated a “buy” rating and issued a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $67.50.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.